U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6N2O2
Molecular Weight 138.124
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of UROCANIC ACID

SMILES

OC(=O)\C=C\C1=CNC=N1

InChI

InChIKey=LOIYMIARKYCTBW-OWOJBTEDSA-N
InChI=1S/C6H6N2O2/c9-6(10)2-1-5-3-7-4-8-5/h1-4H,(H,7,8)(H,9,10)/b2-1+

HIDE SMILES / InChI

Molecular Formula C6H6N2O2
Molecular Weight 138.124
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Urocanic acid is a breakdown (deamination) product of histidine. In the liver, urocanic acid is an intermediate in the conversion of histidine to glutamic acid, whereas in the epidermis, it accumulates and may be both a UV protectant and an immunoregulator. Urocanic acid (UA) exists as a trans isomer (t-UA, approximately 30 mg/cm2) in the uppermost layer of the skin (stratum corneum). t-UA is formed as the cells of the second layer of skin become metabolically inactive. During this process, proteins and membranes degrade, histidine is released, and histidase (histidine ammonia lyase) catalyzes the deamination of histidine to form t-UA. t-UA accumulates in the epidermis until removal by either the monthly skin renewal cycle or sweat. Upon absorption of UV light, the naturally occurring t-UA isomerizes to its cis form, c-UA. Because DNA lesions (e. g. , pyrimidine dimers) in the lower epidermis can result from UV-B absorption, initial research proposed that t-UA acted as a natural sunscreen absorbing UV-B in the stratum corneum before the damaging rays could penetrate into lower epidermal zones. c-UA also suppresses contact hypersensitivity and delayed hypersensitivity, reduces the Langerhans cell count in the epidermis, prolongs skin-graft survival time, and affects natural killer cell activity. It has also been proposed that c-UA may mediate the transient alteration in immune surveillance resulting in immunosuppression induced after UV-irradiation, by interacting with immune cells locally and/or systemically to generate T cells with suppressor function.

Approval Year

PubMed

PubMed

TitleDatePubMed
Measurement of the skin urocanic acid content in normal and histidinemic infants.
1983 Sep
High-performance liquid chromatographic determination of (Z)-and (E)-urocanic acid in human skin.
1984 Sep 14
Photochemistry and photobiology of urocanic acid.
1985 Jun
Urocanic acid concentration and photoisomerization in Caucasian skin phototypes.
1997 May
The potential role for urocanic acid and sunlight in the immune suppression associated with protein malnutrition.
1998 Jul 10
Molecular mechanisms of cis-urocanic acid and permethrin-induced alterations in cutaneous immunity.
2003 Dec
Ring-substituted imidazoles as a new class of anti-tuberculosis agents.
2004 Sep
The effect of clinical UVA/B exposures on urinary urocanic acid isomer levels in individuals with caucasian type (II/III) skin types.
2005 Dec 1
Patents

Sample Use Guides

A combination of the trans- and cis-isomers of urocanic acid (200 ug/ml) induced cAMP in both CD16+ and CD16- cells, but individual, stereospecific effects were not demonstrable.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:48:14 GMT 2023
Edited
by admin
on Fri Dec 15 19:48:14 GMT 2023
Record UNII
G8D26XJJ3B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UROCANIC ACID
INCI  
INCI  
Official Name English
(E)-UROCANIC ACID
Common Name English
2-PROPENOIC ACID, 3-(1H-IMIDAZOL-4-YL)-, (E)-
Common Name English
(E)-3-(4-IMIDAZOLYL)ACRYLIC ACID
Systematic Name English
UROCANIC ACID [INCI]
Common Name English
NSC-66357
Code English
IMIDAZOLE-4-ACRYLIC ACID, (E)-
Common Name English
(E)-3-(IMIDAZOL-4-YL)-2-PROPENOIC ACID
Systematic Name English
TRANS-UROCANIC ACID
Common Name English
UROCANIC ACID, TRANS-
Common Name English
UROCANINIC ACID
Common Name English
Code System Code Type Description
CAS
104-98-3
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
ALTERNATIVE
CHEBI
30817
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
ECHA (EC/EINECS)
203-258-4
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
CAS
3465-72-3
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
NSC
66357
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
DRUG BANK
DB01971
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
FDA UNII
G8D26XJJ3B
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
WIKIPEDIA
UROCANIC ACID
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
PUBCHEM
736715
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
MESH
D014560
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID5041148
Created by admin on Fri Dec 15 19:48:14 GMT 2023 , Edited by admin on Fri Dec 15 19:48:14 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE